# US Non Alcoholic Steatohepatitis Biomarkers Market > US Non-Alcoholic Steatohepatitis Biomarkers Market Research Report By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Others) and By End User (Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 12.27% - **2024:** $ 42 Million - **2025:** $ 47.15 Million - **2035:** $ 150 Million - **Key Players:** F. Hoffmann-La Roche Ltd (CH), AbbVie Inc. (US), Gilead Sciences Inc. (US), Merck & Co., Inc. (US), Amgen Inc. (US), Pfizer Inc. (US), Eli Lilly and Company (US), Novartis AG (CH), Bristol-Myers Squibb Company (US) **Report ID:** MRFR/HC/17924-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-non-alcoholic-steatohepatitis-biomarkers-market-19471 --- ## Market Summary ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Overview** As per MRFR analysis, the US Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at 33.6 (USD Million) in 2023. The US Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to grow from 43.5(USD Million) in 2024 to 560.4 (USD Million) by 2035. The US Non-Alcoholic Steatohepatitis Biomarkers Market CAGR (growth rate) is expected to be around 26.157% during the forecast period (2025 - 2035). ### **Key US Non-Alcoholic Steatohepatitis Biomarkers Market Trends Highlighted** The US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is experiencing significant momentum, driven primarily by the rising prevalence of obesity and metabolic syndrome among the population. As more individuals in the United States face health challenges related to these conditions, there is an increased focus on early detection and management of NASH, fostering demand for reliable biomarkers. The growing awareness of liver diseases, supported by public health initiatives, is also propelling growth in the market. Regulatory bodies, such as the FDA, are pushing for more rigorous testing and validation of biomarkers, which encourages research and development in this area. In recent times, advancements in technology have facilitated the discovery of novel biomarkers that are more effective in diagnosing and monitoring NASH. This trend is appealing to researchers and healthcare providers, as it offers improved patient outcomes through personalized treatment plans. Additionally, increased funding for research institutions and biopharmaceutical companies in the US has opened new opportunities for innovation in NASH diagnostics. Data sharing initiatives among research communities are further streamlining the development process, leading to faster translations of laboratory findings into clinical applications. Moreover, the demographic shift towards an aging population in the US is expected to increase the burden of chronic liver diseases, including NASH. This presents opportunities for servicing an evolving market that is adapting to meet the specific needs of older adults. Collaborative efforts among stakeholders, such as pharmaceutical companies and healthcare organizations, aim to enhance awareness, support screening programs, and improve the overall understanding of NASH, paving the way for future growth in the biomarkers sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Drivers** ### **Rising Prevalence of Non-Alcoholic Steatohepatitis (NASH)** The increasing number of individuals diagnosed with Non-Alcoholic Steatohepatitis in the United States significantly fuels growth in the US Non-Alcoholic Steatohepatitis Biomarkers Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 30% of American adults are estimated to have non-alcoholic fatty liver disease (NAFLD), of which a substantial percentage progresses to NASH. This translates to millions of individuals at risk for advanced liver disease, necessitating effective biomarker development for early detection and diagnosis. As awareness and diagnosis of NASH continue to grow, companies like Genfit and Intercept Pharmaceuticals are actively investing in Research and Development of novel biomarkers, paving the way for advancement in patient care and driving market growth. Moreover, initiatives such as the Healthy People 2030 set by the U.S. Department of Health and Human Services aim to reduce the health consequences of NAFLD and NASH, generating further research and innovation in this field. ### **Increased Investment in Research and Development** The surge in investment in Research and Development for Non-Alcoholic Steatohepatitis biomarkers is a critical driver for the US Non-Alcoholic Steatohepatitis Biomarkers Market Industry. The National Institutes of Health (NIH) allocated over USD 2.5 billion to liver disease research in recent years, reflecting a significant commitment to understanding the complexities of NASH and related biomarkers. This financial backing not only enables researchers and companies to develop cutting-edge diagnostic tools but also encourages collaborations between academic institutions and businesses. As more entities, such as the American Liver Foundation, advocate for advancements in NASH treatment, the demand for effective biomarkers capable of early diagnosis and intervention is poised to rise, ensuring continuous market growth over the coming years. ### **Growing Awareness and Screening for Liver Diseases** As the public becomes increasingly aware of liver diseases, particularly Non-Alcoholic Steatohepatitis, the US Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to experience significant growth. Campaigns led by organizations such as the American Association for the Study of Liver Diseases (AASLD) have played a crucial role in educating the public about the importance of liver health. A survey conducted by the organization revealed that 70% of respondents felt they lacked sufficient knowledge about liver diseases. This heightened awareness has fostered an environment where more individuals are seeking screening and diagnosis, leading to a surge in the demand for biomarkers tailored for early identification and management of NASH, thus positively influencing market expansion. ### **Technological Advancements in Diagnostics** The rapid advancement of technology has revolutionized the diagnostic landscape in the US Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Innovations in genomics, proteomics, and metabolomics are facilitating the development of highly sensitive and specific biomarkers. The U.S. Food and Drug Administration (FDA) has increasingly been approving new diagnostic tests, reflecting confidence in technological progress and its potential to improve patient outcomes. For example, the recent approval of non-invasive biomarkers like the FibroScan by Echosens has dramatically changed how NASH is diagnosed and monitored, eliminating the need for invasive liver biopsies. As these technologies become more accessible and integrated into clinical practice, they are expected to enhance the early detection and treatment of NASH, thereby driving market demand forward. ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Segment Insights** ### **Non-Alcoholic Steatohepatitis Biomarkers Market Type Insights** The US Non-Alcoholic Steatohepatitis Biomarkers Market experiences significant growth propelled by Type segmentation, which includes various biomarkers that are crucial for the diagnosis and monitoring of this liver condition. Hepatic Fibrosis Biomarkers play a vital role in assessing the severity of liver damage, with growing emphasis on their predictive capabilities for disease progression. These biomarkers are increasingly integrated into standard clinical practices to improve patient outcomes, making them a prominent feature of the market landscape. Serum Biomarkers provide essential insights into liver inflammation and damage, serving as non-invasive tools that enhance diagnostic accuracy and facilitate patient management. The importance of these biomarkers is underscored by the rising incidences of obesity and metabolic disorders in the US, which are closely related to the prevalence of Non-Alcoholic Steatohepatitis. Oxidative Stress Biomarkers are also gaining traction in market discussions, as their analysis reveals critical information about cellular damage and the underlying mechanisms of disease progression. As research expands, these biomarkers present an opportunity for novel therapeutic approaches. Furthermore, Apoptosis Biomarkers contribute significantly to understanding the pathological processes of Non-Alcoholic Steatohepatitis. Their significance lies in the ability to elucidate cellular death mechanisms, which are integral to developing effective treatments. The other categories encompass a diverse range of biomarkers that may yield important insights into the complex interactions of metabolic pathways associated with liver health. Overall, the Type classification within the US Non-Alcoholic Steatohepatitis Biomarkers Market underscores the complexity of diagnosing and managing this condition. The steady rise in awareness and diagnostic requirements among healthcare professionals drives demand for advanced biomarker applications, ultimately positioning the market for an upward trajectory as health concerns linked to liver diseases continue to escalate in the US population. Each type of biomarker addresses unique aspects of disease pathology, contributing to a comprehensive approach in the monitoring and treatment strategies for Non-Alcoholic Steatohepatitis. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Non-Alcoholic Steatohepatitis Biomarkers Market End User Insights** The US Non-Alcoholic Steatohepatitis Biomarkers Market is characterized by a diverse range of End Users, each playing a pivotal role in driving market growth and innovation. Research Institutes and Academics contribute significantly to the development of novel biomarkers, facilitating improvements in diagnosis and treatment of Non-Alcoholic Steatohepatitis. Diagnostic Centres hold a critical position in enabling early detection and monitoring of the disease, directly impacting patient outcomes. Pharmaceutical Companies and Contract Research Organizations (CROs) are instrumental in advancing research and development, focusing on biomarkers critical to drug discovery and therapeutic strategies. Hospitals and Clinics serve as essential frontline institutions for patient care, integrating biomarkers into routine clinical practice to enhance disease management. Other categories encompass a broad array of service providers and emerging players who support the overall ecosystem. This dynamic segmentation structure indicates that each End User not only fulfills a distinct function within the US Non-Alcoholic Steatohepatitis Biomarkers Market but also highlights the collaborative nature of the market landscape, essential for tackling the challenges posed by this growing health concern. ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Key Players and Competitive Insights** The US Non-Alcoholic Steatohepatitis Biomarkers Market is witnessing robust growth due to the increasing prevalence of liver diseases and the rising awareness among healthcare professionals regarding the significance of early diagnosis and effective management of non-alcoholic steatohepatitis (NASH). The competitive landscape in this market is dynamic, with several key players striving to develop innovative biomarker tests that can assist in the timely identification of NASH in patients. The focus on research and development is significant, with companies investing heavily in clinical trials and partnerships to enhance the diagnostic capabilities and treatment options available. Additionally, as government support and funding for liver disease research are increasing, more stakeholders are entering the market, raising the competition substantially. Fujirebio has established a solid presence in the US Non-Alcoholic Steatohepatitis Biomarkers Market through its commitment to pioneering diagnostics in the field of liver diseases. The company's strengths lie in its extensive portfolio of innovative biomarker tests and its strong relationships with healthcare providers, enabling it to reach a wide audience. Fujirebio's deep expertise in biomarker discovery and development, coupled with robust research capabilities, allows it to stay at the forefront of advancements in NASH diagnostics. The company's dedication to improving patient outcomes and enhancing the accuracy of NASH diagnosis demonstrates its leadership position within the market. Furthermore, Fujirebio's strategic collaborations with research institutions and healthcare organizations in the US foster innovation and facilitate the introduction of new products catering specifically to the healthcare needs associated with non-alcoholic fatty liver disease. Prometheus Biosciences is a notable player in the US Non-Alcoholic Steatohepatitis Biomarkers Market, recognized for its focus on advancing precision medicine for liver diseases. The company offers a range of key products and services that target biomarkers related to NASH, positioning itself as a pivotal entity in biomarker development and application. Its market presence is further fortified by its proactive approach to research and product development, enhancing its portfolio with innovative solutions that align with the emerging demands of healthcare providers. Prometheus Biosciences has made strategic moves through mergers and acquisitions that bolster its capabilities and market reach. The emphasis on developing cutting-edge diagnostic tests and fostering relationships with medical professionals underscores its strength in addressing the clinical scenarios posed by NASH. Moreover, Prometheus's aim to facilitate comprehensive treatment options for patients creates a competitive advantage, as it aligns with the growing trend of personalized medicine in the US healthcare landscape. ### **Key Companies in the US Non-Alcoholic Steatohepatitis Biomarkers Market Include** ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Industry Developments** Recent developments in the US Non-Alcoholic Steatohepatitis Biomarkers Market indicate a dynamic growth trajectory, fueled by increased research and heightened awareness of the condition. Companies like Gilead Sciences and AbbVie have been actively expanding their product pipelines to address the NASH epidemic, with promising therapies undergoing extensive clinical trials. Notably, in April 2023, Thermo Fisher Scientific announced a strategic partnership with Interpace Biosciences to enhance biomarker research capabilities, demonstrating a focus on collaboration within the industry. Additionally, in January 2023, Roche's acquisition of a diagnostics firm specializing in liver disease biomarkers underscored a trend toward consolidation as companies aim to solidify their positions. The market valuation for Non-Alcoholic Steatohepatitis biomarkers has seen significant growth, driven by innovations and advancing technologies, particularly in non-invasive testing methods. Moreover, the US market's landscape has evolved with increased regulatory support and funding for Research and Development of NASH therapies, attracting investments and partnerships. Over the past two to three years, the sector has benefited from heightened FDA engagement and a renewed commitment to addressing the growing prevalence of NASH, particularly among the rising demographic of obese patients in the US. ## **US Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation Insights** ### **Non-Alcoholic Steatohepatitis Biomarkers Market Type Outlook** ### **Non-Alcoholic Steatohepatitis Biomarkers Market End User Outlook** ## Market Drivers ### Rising Focus on Personalized Medicine The increasing emphasis on personalized medicine is shaping the landscape of the non alcoholic-steatohepatitis-biomarkers market. As healthcare moves towards tailored treatment approaches, the need for specific biomarkers that can predict individual responses to therapies becomes paramount. In the US, the shift towards personalized medicine is supported by advancements in genomics and proteomics, which enable the identification of unique biomarkers associated with NASH. This trend is likely to enhance the development of targeted therapies and improve patient outcomes. Consequently, the non alcoholic-steatohepatitis-biomarkers market is expected to benefit from this focus on personalized approaches, as stakeholders seek to develop biomarkers that align with the principles of individualized care. ### Growing Incidence of Metabolic Disorders The rising incidence of metabolic disorders, particularly obesity and type 2 diabetes, is a crucial driver for the non alcoholic-steatohepatitis-biomarkers market. In the US, approximately 42.4% of adults are classified as obese, which significantly increases the risk of developing non alcoholic fatty liver disease (NAFLD) and its more severe form, non alcoholic steatohepatitis (NASH). This alarming trend necessitates the development of effective biomarkers for early diagnosis and monitoring of liver health. As healthcare providers seek to address the growing burden of these metabolic conditions, the demand for reliable biomarkers is expected to surge, thereby propelling the growth of the non alcoholic-steatohepatitis-biomarkers market. Furthermore, the increasing healthcare costs associated with managing these disorders further emphasize the need for early detection and intervention. ### Regulatory Support for Biomarker Development Regulatory bodies in the US are increasingly recognizing the importance of biomarkers in the diagnosis and management of liver diseases, including NASH. The FDA has established pathways to expedite the approval of novel biomarkers, which is likely to enhance the non alcoholic-steatohepatitis-biomarkers market. Initiatives such as the Biomarker Qualification Program aim to facilitate the development and validation of biomarkers, thereby streamlining the process for researchers and companies. This regulatory support not only encourages innovation but also instills confidence in stakeholders regarding the efficacy and safety of new biomarkers. As a result, the non alcoholic-steatohepatitis-biomarkers market is poised for growth, driven by a favorable regulatory environment that promotes the introduction of advanced diagnostic tools. ### Growing Demand for Non-Invasive Diagnostic Tools The demand for non-invasive diagnostic tools is rapidly increasing in the healthcare landscape, particularly for liver diseases. Patients and healthcare providers are increasingly favoring non-invasive methods over traditional liver biopsies due to their associated risks and discomfort. This shift in preference is driving the non alcoholic-steatohepatitis-biomarkers market, as new biomarkers are being developed to facilitate non-invasive assessments of liver health. Technologies such as imaging techniques and blood-based biomarkers are gaining traction, offering reliable alternatives for diagnosing NASH. As awareness of the benefits of non-invasive diagnostics continues to grow, the market for non alcoholic-steatohepatitis-biomarkers is likely to experience significant growth, catering to the evolving needs of patients and clinicians. ### Increased Investment in Research and Development Investment in research and development (R&D) for liver diseases is witnessing a notable increase, which serves as a significant driver for the non alcoholic-steatohepatitis-biomarkers market. Pharmaceutical companies and research institutions are allocating substantial resources to discover and validate new biomarkers that can aid in the diagnosis and treatment of NASH. In 2025, it is estimated that R&D spending in the healthcare sector will reach approximately $200 billion in the US, with a considerable portion directed towards liver disease research. This influx of funding is likely to accelerate the pace of biomarker discovery, leading to innovative solutions that address the unmet needs in the management of NASH. Consequently, the non alcoholic-steatohepatitis-biomarkers market is expected to expand as new biomarkers are developed and brought to market. ## Future Outlook The [Non Alcoholic Steatohepatitis Biomarkers Market](https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984) is projected to grow at a 12.27% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in diagnostic technologies. **New opportunities:** - Development of point-of-care testing devices for rapid diagnosis. Partnerships with biotech firms for innovative biomarker discovery. Expansion into telehealth services for remote patient monitoring. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Hepatic Fibrosis Biomarkers (Largest) vs. Serum Biomarkers (Fastest-Growing) In the US non alcoholic-steatohepatitis-biomarkers market, the major segments include Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, and Others. Among these, Hepatic Fibrosis Biomarkers hold the largest market share owing to their critical role in diagnosing and evaluating disease severity. Serum Biomarkers are gaining traction as they offer non-invasive testing options, leading to an increase in their adoption within healthcare settings. The growth trends indicate a significant rise in demand for Serum Biomarkers, as they present an emerging solution for efficient monitoring and management of non-alcoholic steatohepatitis. The market is driven by advancements in biomarker technologies, increasing awareness of liver diseases, and a strong push towards personalized medicine. Additionally, the regulatory approval of innovative biomarkers is further bolstering growth in this segment. Hepatic Fibrosis Biomarkers (Dominant) vs. Serum Biomarkers (Emerging) Hepatic Fibrosis Biomarkers are a dominant segment in the US non alcoholic-steatohepatitis-biomarkers market, characterized by their established role in liver disease diagnosis and management. They provide crucial insights into the degree of liver damage and fibrosis, making them essential in clinical practice. On the other hand, Serum Biomarkers represent an emerging category, known for their non-invasive nature and convenience, gradually gaining acceptance among healthcare professionals. Their development is fueled by innovative research, with a broad spectrum of applications in monitoring disease progression and treatment efficacy. As awareness of liver health continues to grow, these biomarkers are expected to play a pivotal role in enhancing patient outcomes. ### By End User: Hospitals and Clinics (Largest) vs. Diagnostic Centres (Fastest-Growing) In the US non alcoholic-steatohepatitis-biomarkers market, the distribution of market share among end user segments is notably varied. Hospitals and clinics hold the largest share due to their critical role in patient care and diagnosis, utilizing biomarker tests to manage liver diseases effectively. Additionally, diagnostic centres are gaining traction, driven by advancements in testing technologies and a growing demand for precise diagnostics. The growth trends in this segment are fueled by several factors, including an increase in the prevalence of non-alcoholic steatohepatitis (NASH) and the rising awareness of liver health among patients. Moreover, partnerships between pharmaceutical companies and diagnostic centres are strengthening the market, facilitating the development of innovative biomarker tests. As healthcare systems continue to emphasize early diagnosis and intervention, diagnostic centres are positioned for rapid growth. Hospitals and Clinics (Dominant) vs. Diagnostic Centres (Emerging) Hospitals and clinics represent the dominant end user segment in the US non alcoholic-steatohepatitis-biomarkers market, as they provide comprehensive healthcare services and have direct access to patient populations requiring NASH-related diagnostics. Their established infrastructure and ability to implement advanced testing protocols enable them to utilize biomarkers effectively for early detection and treatment planning. Conversely, diagnostic centres are emerging as significant players, capitalizing on the increasing demand for specialized testing services. They offer streamlined processes, quicker turnaround times, and often focus exclusively on diagnostic services, making them an appealing option for both patients and healthcare providers. This shift towards more dedicated diagnostic facilities is set to shape the future dynamics of the market. ## Competitive Benchmarking The non alcoholic-steatohepatitis-biomarkers market is currently characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing emphasis on early diagnosis and personalized treatment. Key players such as AbbVie Inc. (US), Gilead Sciences Inc. (US), and Merck & Co., Inc. (US) are strategically positioning themselves through innovation and partnerships. AbbVie Inc. (US) has focused on expanding its pipeline of biomarkers, which appears to enhance its competitive edge in the market. Gilead Sciences Inc. (US) is leveraging its expertise in liver diseases to develop novel diagnostic tools, while Merck & Co., Inc. (US) is investing in digital health solutions to streamline patient management and improve outcomes. Collectively, these strategies are shaping a competitive environment that prioritizes innovation and patient-centric approaches.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they drive advancements in biomarker development and diagnostic technologies, thereby setting industry standards. In October AbbVie Inc. (US) announced a collaboration with a leading biotechnology firm to co-develop a novel biomarker for non alcoholic steatohepatitis (NASH). This partnership is expected to accelerate the development of diagnostic tools, potentially positioning AbbVie as a leader in the NASH biomarker space. The strategic importance of this collaboration lies in its potential to enhance AbbVie's product offerings and expand its market reach. In September Gilead Sciences Inc. (US) launched a new digital platform aimed at improving patient engagement and monitoring for those at risk of NASH. This initiative reflects Gilead's commitment to integrating technology into its treatment protocols, which may lead to better patient outcomes and increased adherence to treatment regimens. The launch signifies a shift towards more holistic patient management strategies in the NASH landscape. In August Merck & Co., Inc. (US) unveiled a new biomarker discovery program focused on identifying early indicators of NASH progression. This program is anticipated to enhance Merck's research capabilities and foster innovation in biomarker development. The strategic move underscores Merck's dedication to addressing unmet needs in the NASH market and reinforces its position as a key player in the field. As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in biomarker research and development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift may redefine market dynamics, emphasizing the importance of agility and responsiveness in meeting the needs of healthcare providers and patients. ## Recent News & Developments Recent developments in the US Non-Alcoholic Steatohepatitis Biomarkers Market indicate a dynamic growth trajectory, fueled by increased research and heightened awareness of the condition. Companies like Gilead Sciences and AbbVie have been actively expanding their product pipelines to address the NASH epidemic, with promising therapies undergoing extensive clinical trials. Notably, in April 2023, Thermo Fisher Scientific announced a strategic partnership with Interpace Biosciences to enhance biomarker research capabilities, demonstrating a focus on collaboration within the industry. Additionally, in January 2023, Roche's acquisition of a diagnostics firm specializing in liver disease biomarkers underscored a trend toward consolidation as companies aim to solidify their positions. The market valuation for Non-Alcoholic Steatohepatitis biomarkers has seen significant growth, driven by innovations and advancing technologies, particularly in non-invasive testing methods. Moreover, the US market's landscape has evolved with increased regulatory support and funding for Research and Development of NASH therapies, attracting investments and partnerships. Over the past two to three years, the sector has benefited from heightened FDA engagement and a renewed commitment to addressing the growing prevalence of NASH, particularly among the rising demographic of obese patients in the US. ## Report Scope | MARKET SIZE 2024 | 42.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 47.15(USD Million) | | MARKET SIZE 2035 | 150.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 12.27% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | F. Hoffmann-La Roche Ltd (CH), AbbVie Inc. (US), Gilead Sciences Inc. (US), Merck & Co., Inc. (US), Amgen Inc. (US), Pfizer Inc. (US), Eli Lilly and Company (US), Novartis AG (CH), Bristol-Myers Squibb Company (US) | | Segments Covered | Type, End User | | Key Market Opportunities | Advancements in biomarker discovery enhance diagnostic accuracy in the non alcoholic-steatohepatitis-biomarkers market. | | Key Market Dynamics | Rising demand for non alcoholic steatohepatitis biomarkers drives innovation and regulatory scrutiny in diagnostics. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US non alcoholic-steatohepatitis-biomarkers market in 2024?** A: The market valuation was $42.0 Million in 2024. **Q: What is the projected market valuation for the US non alcoholic-steatohepatitis-biomarkers market by 2035?** A: The projected valuation for 2035 is $150.0 Million. **Q: What is the expected CAGR for the US non alcoholic-steatohepatitis-biomarkers market during the forecast period 2025 - 2035?** A: The expected CAGR is 12.27% during the forecast period 2025 - 2035. **Q: Which segment had the highest valuation in the US non alcoholic-steatohepatitis-biomarkers market in 2024?** A: The Pharmaceutical Companies and CROs segment had the highest valuation at $12.0 Million in 2024. **Q: What are the projected values for Hepatic Fibrosis Biomarkers in the US non alcoholic-steatohepatitis-biomarkers market?** A: The projected values for Hepatic Fibrosis Biomarkers range from $10.0 Million to $35.0 Million. **Q: Which key players are leading the US non alcoholic-steatohepatitis-biomarkers market?** A: Key players include F. Hoffmann-La Roche Ltd, AbbVie Inc., and Gilead Sciences Inc. **Q: What is the valuation range for Serum Biomarkers in the US non alcoholic-steatohepatitis-biomarkers market?** A: The valuation range for Serum Biomarkers is from $12.0 Million to $40.0 Million. **Q: How did the market for Apoptosis Biomarkers perform in 2024?** A: The market for Apoptosis Biomarkers was valued between $6.0 Million and $20.0 Million in 2024. **Q: What is the expected growth trend for the US non alcoholic-steatohepatitis-biomarkers market?** A: The market is expected to grow significantly, reaching $150.0 Million by 2035. **Q: What is the valuation range for the Diagnostic Centres segment in the US non alcoholic-steatohepatitis-biomarkers market?** A: The valuation range for Diagnostic Centres is from $8.0 Million to $30.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-non-alcoholic-steatohepatitis-biomarkers-market-19471*